Literature DB >> 3300835

Cyclosporin A in the treatment of severe Behçet's uveitis.

A I Binder, E M Graham, M D Sanders, W Dinning, D G James, A M Denman.   

Abstract

Twelve patients with active Behçet's uveitis with marked deterioration of visual acuity in at least one eye were treated with cyclosporin A (CyA). An initial improvement in the severity of ocular inflammation and systemic features occurred in all cases and persisted until the dose was reduced or the drug withdrawn when a rapid recurrence of symptoms was noted. The visual acuity also initially improved in ten patients and this was maintained in seven cases until the dose of CyA was reduced. At this time, acuity was unchanged in two patients and was worse in three others-two of the latter as a result of vitreous haemorrhage in the absence of active inflammation. Seven of the 12 patients had therapy stopped because of complications; severe malaise and nausea (three cases), decreased renal function (three cases), and blindness (one case). Cyclosporin A is of value in the control of Behçet's uveitis but toxicity limits its use and the benefits only last while the patient is on this therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300835     DOI: 10.1093/rheumatology/26.4.285

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  12 in total

Review 1.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.

Authors:  Y Ozyazgan; S Yurdakul; H Yazici; B Tüzün; A Işçimen; Y Tüzün; T Aktunç; H Pazarli; V Hamuryudan; A Müftüoğlu
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

Review 3.  Retinal vasculitis.

Authors:  M D Sanders; E M Graham
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

Review 4.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

5.  Precipitation of experimental autoallergic uveoretinitis by cyclosporin A withdrawal: an experimental model of uveitis relapse.

Authors:  E G Atkinson; W J Dinning; E Kasp; E M Graham; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

6.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

8.  Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease.

Authors:  P S Chavis; S R Antonios; K F Tabbara
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

Review 9.  Current and future treatments for Behçet's uveitis: road to remission.

Authors:  Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán
Journal:  Int Ophthalmol       Date:  2013-06-01       Impact factor: 2.031

10.  Cyclosporine for ocular inflammatory diseases.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Ebenezer Daniel; Sapna Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; C Stephen Foster
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.